A Phase Ib, Open-Label, Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Inclusion Criteria:

- Histologic documentation of incurable, locally advanced, or metastatic solid
malignancy that has failed to respond to at least one prior regimen or for which
there is no standard therapy

- Documented negative serum pregnancy test for women of childbearing potential and use
of two forms of contraception. Contraception must be used while the patient is
enrolled in the study and for 12 months after the patient discontinues from the
study.

- For men with female partners of childbearing potential, agreement to use a latex
condom and to advise their female partner to use an additional method of
contraception during the study and for 3 months after their last dose of GDC-0449.

- Agreement not to donate blood or blood products during the study and for at least 12
months after their last dose of GDC-0449

- For male patients, agreement not to donate sperm during the study and for at least 3
months after their last dose of GDC-0449

- Adequate hematopoietic capacity

- Adequate renal function

- Adequate hepatic function

- At least 3 weeks since the patient's last chemotherapy, investigational agent,
radiation therapy, or major surgical procedure and recovery to pre-treatment baseline
or stabilization of all treatment-related toxicities

Exclusion Criteria:

- Active infection requiring intravenous (IV) antibiotics

- Clinically important history of liver disease significantly impairing hepatic
function, including active viral or other hepatitis, current alcohol abuse, or
cirrhosis

- Any medical condition or diagnosis that would likely impair absorption of an orally
administered drug

- Pregnant or lactating

- Treatment with excluded medications, including strong CYP450 inhibitors and inducers,
within 2 weeks of study entry

- Male patients already receiving rosiglitazone

- Male patients with a known contraindication to rosiglitazone

- Female patients already receiving oral contraception < 14 days prior to Day 1

- Female patients with known contraindication to oral contraceptions